This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trouet, A. Articles by Dubois, V. Search for Related Content PubMed PubMed Citation Articles by Trouet, A. Articles by Dubois, V.

Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer

Application to Doxorubicin and Preliminary in Vitro and in Vivo Studies¹

Université Catholique de Louvain, Laboratory of Cell Biology, B-1348 Louvain-la-Neuve, Belgium [A. T., A. P., K. V. d., A-M. F., J. A-Q., R. B., V. D.], and Corixa, South San Francisco, California 94080 [T. J. L., C. O., D. S.]

Oligopeptidic derivatives of anthracyclines unable to penetrate cells were prepared and screened for their stability in human blood and their reactivation by peptidases secreted by cancer cells. N-ß-alanyl-L-leucyl-L-alanyl-L-leucyl-doxorubicin was selected as a new candidate prodrug. The NH₂-terminal ß-alanine allows a very good blood stability. A two-step activation by peptidases found in conditioned media of cancer cells ultimately yields N-L-leucyl-doxorubicin. In vitro, when MCF-7/6 cancer cells are exposed to the prodrug, they accumulate about 14 times more doxorubicin than MRC-5 normal fibroblasts, whereas when exposed to doxorubicin the uptake is slightly higher in fibroblasts than in MCF-7/6 cells. This increased specificity of the prodrug over doxorubicin was confirmed in cytotoxicity assays using the same cell types. In vivo, the prodrug proved about nine times less toxic than doxorubicin in the normal mouse and also much more efficient in two different experimental chemotherapy models of human breast tumors.

This article has been cited by other articles:

				D. Ravel, V. Dubois, J. Quinonero, F. Meyer-Losic, J. Delord, P. Rochaix, C. Nicolazzi, F. Ribes, C. Mazerolles, E. Assouly, et al. Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin Clin. Cancer Res., February 15, 2008; 14(4): 1258 - 1265. [Abstract] [Full Text] [PDF]

				W. Wu, Y. Luo, C. Sun, Y. Liu, P. Kuo, J. Varga, R. Xiang, R. Reisfeld, K. D. Janda, T. S. Edgington, et al. Targeting Cell-Impermeable Prodrug Activation to Tumor Microenvironment Eradicates Multiple Drug-Resistant Neoplasms Cancer Res., January 15, 2006; 66(2): 970 - 980. [Abstract] [Full Text] [PDF]

				C. F. Albright, N. Graciani, W. Han, E. Yue, R. Stein, Z. Lai, M. Diamond, R. Dowling, L. Grimminger, S.-Y. Zhang, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity Mol. Cancer Ther., May 1, 2005; 4(5): 751 - 760. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				S. Bien, C. A. Ritter, M. Gratz, B. Sperker, J. Sonnemann, J. F. Beck, and H. K. Kroemer Nuclear Factor-{kappa}B Mediates Up-Regulation of Cathepsin B by Doxorubicin in Tumor Cells Mol. Pharmacol., May 1, 2004; 65(5): 1092 - 1102. [Abstract] [Full Text] [PDF]

				C. Pan, P. M. Cardarelli, M. H. Nieder, L. B. Pickford, S. Gangwar, D. J. King, G. T. Yarranton, D. Buckman, W. Roscoe, F. Zhou, et al. CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors Cancer Res., September 1, 2003; 63(17): 5526 - 5531. [Abstract] [Full Text] [PDF]

				F. M. H. de Groot, H. J. Broxterman, H. P. H. M. Adams, A. van Vliet, G. I. Tesser, Y. W. Elderkamp, A. J. Schraa, R. Jan Kok, G. Molema, H. M. Pinedo, et al. Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug Mol. Cancer Ther., September 1, 2002; 1(11): 901 - 911. [Abstract] [Full Text] [PDF]

				V. Dubois, L. Dasnois, K. Lebtahi, F. Collot, N. Heylen, N. Havaux, A.-M. Fernandez, T. J. Lobl, C. Oliyai, M. Nieder, et al. CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin: In Vivo Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity Cancer Res., April 1, 2002; 62(8): 2327 - 2331. [Abstract] [Full Text] [PDF]